Contents


AGALSIDASE BETA

Drug action

Agalsidase beta, an enzyme produced by recombinant DNA technology are licensed for long-term enzyme replacement therapy in Fabry's disease (a lysosomal storage disorder caus...

This item requires a subscription.
For full access to this content, log in to an existing user account or purchase an individual subscription.
×
Sign in or create an account
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. Sign in or purchase a subscription to access this content. ×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. Accept